Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

NCT06912529 is registered in ClinicalTrials.gov with Universität Münster as lead sponsor.

NCT NCT06912529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06912529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
Lead sponsor
Universität Münster
Phase
Phase 2
Overall status
Terminated
Start date
March 13, 2025
Completion date
July 25, 2025
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma recurrent, b-cell lymphoma refractory